Please login to the form below

Not currently logged in
Email:
Password:

M7824

This page shows the latest M7824 news and features for those working in and with pharma, biotech and healthcare.

Immuno-oncology at ASCO: survival data, combinations and new indications

Immuno-oncology at ASCO: survival data, combinations and new indications

Also on the agenda are preliminary clinical results with M7824, an investigational TGF‑beta trap/anti-PD-L1 bi-functional immunotherapy fusion protein in human papillomavirus (HPV)-associated cancers and

Latest news

  • Merck takes novel immuno-oncology drug into clinical trials Merck takes novel immuno-oncology drug into clinical trials

    The bifunctional immunotherapy - called M7824 - was one of the highlights of an R&D update held yesterday at which the company highlighted its pipeline of new drug candidates in its three ... rate. Merck is not ready to divulge the molecular targets for

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics